Literature DB >> 10564591

Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.

R E Reiter1, I Sato, G Thomas, J Qian, Z Gu, T Watabe, M Loda, R B Jenkins.   

Abstract

Gain of sequences on chromosome arm 8q is a common feature of prostate cancer that may correlate with metastatic and androgen-independent progression. The target gene(s) for this gain is not known, although MYC is amplified in a subset of advanced tumors and is one potential candidate. Prostate stem cell antigen (PSCA) is a prostate-specific cell surface protein that maps to chromosome region 8q24.2 and is overexpressed in prostate cancer. Our aim in this study was to test the hypothesis that PSCA overexpression may result from overrepresentation of chromosome arm 8q. Twenty locally advanced prostate cancers were analyzed by dual-probe fluorescence in situ hybridization (FISH) for alterations of MYC and PSCA. Extra copies of MYC were found in 12/20 (60%) tumors, including 5 (25%) with simple gain (no increase in MYC copy number relative to the chromosome 8 centromere) and 7 (35%) with an additional increase (AI or overrepresentation) in MYC copy number relative to the centromere. In the five cases with simple gain of MYC, there was a concomitant gain of PSCA. PSCA was overrepresented in 5/7 (71%) cases with AI of MYC. Immunohistochemical staining of the 20 tumors with monoclonal antibodies specific for PSCA showed a high degree of correlation between PSCA gene overrepresentation and protein overexpression. Four of 5 tumors with AI of PSCA overexpressed PSCA protein, compared with only 2/15 tumors with a normal PSCA copy number or simple gain of PSCA (P = 0.014). These results demonstrate that PSCA is co-overrepresented with MYC in a majority of cases, but may not be a necessary part of the 8q amplicon. PSCA protein overexpression can result from AI of PSCA and might be useful as a cell surface marker on prostate cancer cells with 8q overrepresentation. Genes Chromosomes Cancer 27:95-103, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10564591     DOI: 10.1002/(sici)1098-2264(200001)27:1<95::aid-gcc12>3.0.co;2-3

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

Review 1.  Prostate stem cell antigen: a Jekyll and Hyde molecule?

Authors:  Norihisa Saeki; Jian Gu; Teruhiko Yoshida; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 2.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

Review 3.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

4.  Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis.

Authors:  S Ross; S D Spencer; L A Lasky; H Koeppen
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 5.  Molecular biology in prostate cancer.

Authors:  José Ramón Cansino Alcaide; Luis Martínez-Piñeiro
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

6.  Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer.

Authors:  Norihiko Tsuchiya; Yasushi Kondo; Atsushi Takahashi; Hemant Pawar; Junqi Qian; Kazunari Sato; Michael M Lieber; Robert B Jenkins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

7.  Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.

Authors:  D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

8.  MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Authors:  Bala S Balakumaran; Alessandro Porrello; David S Hsu; Wayne Glover; Adam Foye; Janet Y Leung; Beth A Sullivan; William C Hahn; Massimo Loda; Phillip G Febbo
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

9.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Robert B Jenkins; Fusheng Lan; Chi Van Dang; Jessica L Hicks; James Morgan; Toby C Cornish; Siobhan Sutcliffe; William B Isaacs; Jun Luo; Angelo M De Marzo
Journal:  Mod Pathol       Date:  2008-06-20       Impact factor: 7.842

10.  Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.

Authors:  Jin Zhao; Xin-Yang Wu; Xiao-Hui Ling; Zhuo-Yuan Lin; Xin Fu; Ye-Han Deng; Hui-Chan He; Weide Zhong
Journal:  Med Oncol       Date:  2013-02-03       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.